Boston Scientific
BSX
41.98
-1.01
-2.35%
Boston Scientific
US · BSX
#364 by market cap
Listed 1970
41.98
-1.01
-2.35%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Quant vs Street three independent views, side by side
StockVane factor grade
B+
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Deteriorating
9
■ Upgrades■ Downgrades
- 0 upgrades vs 9 downgrades among tracked analyst rating changes.
- Most recent: Oppenheimer moved from Buy to Hold on 2026-10-29.
Analyst consensus 22 analysts
Buy
Avg price target 50.05 +19.2%
Price target rangecurrent 41.98
Low44.00
Avg50.05
High60.00
Buy 64%
Hold 36%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-19 | Citi | -- | Hold | 44.00 |
| 2026-11-18 | Citi | -- | Hold | 44.00 |
| 2026-11-03 | CCORF | -- | Buy | 48.00 |
| 2026-11-02 | Argus Research | -- | Hold | -- |
| 2026-11-02 | J.P. Morgan | -- | Hold | -- |
| 2026-11-01 | Citi | -- | Hold | 44.00 |
| 2026-10-30 | TD Cowen | -- | Hold | 46.00 |
| 2026-10-30 | BofA Securities | -- | Buy | 54.00 |
| 2026-10-30 | Barclays | -- | Hold | 45.00 |
| 2026-10-29 | TD Cowen | -- | Hold | 46.00 |
| 2026-10-29 | CCORF | -- | Buy | 48.00 |
| 2026-10-29 | Bernstein | -- | Buy | 49.00 |
| 2026-10-29 | UBS | -- | Buy | 57.00 |
| 2026-10-29 | Mizuho Securities | -- | Buy | 50.00 |
| 2026-10-29 | Baird | -- | Buy | 51.00 |
| 2026-10-29 | Deutsche Bank | -- | Buy | 48.00 |
| 2026-10-29 | Citi | -- | Hold | 44.00 |
| 2026-10-29 | Leerink Partners | -- | Buy | 50.00 |
| 2026-10-29 | Barclays | -- | Hold | 48.00 |
| 2026-10-29 | Oppenheimer | -- | Hold | -- |
| 2026-10-28 | BTIG | -- | Buy | 49.00 |
| 2026-10-28 | Jefferies | -- | Hold | 46.00 |
| 2026-10-28 | Needham | -- | Buy | 48.00 |
| 2026-10-28 | RBC Capital | -- | Buy | 52.00 |
| 2026-10-28 | J.P. Morgan | -- | Hold | 46.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-10-29 | Oppenheimer | Buy → Hold | -- |
| 2026-10-29 | TD Cowen | Buy → Hold | 46.00 |
| 2026-10-28 | Jefferies | Buy → Hold | 46.00 |
| 2026-10-28 | J.P. Morgan | Buy → Hold | 46.00 |
| 2026-10-07 | Barclays | Buy → Hold | 48.00 |
| 2026-09-17 | Citi | Buy → Hold | 50.00 |
| 2026-07-30 | Argus Research | Buy → Hold | -- |
| 2026-05-29 | Wolfe Research | Buy → Hold | -- |
| 2026-05-28 | Wells Fargo | Buy → Hold | 55.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-10-28 | -- | ±7.57% | -5.84% (in line) |
| 2026/Q2 | 2026-07-29 | -- | ±7.84% | -0.04% (in line) |
| 2026/Q1 | 2026-04-22 | -- | ±5.97% | +8.99% (beat) |
| 2025/Q4 | 2026-02-04 | -- | ±4.71% | -17.59% (beat) |
| 2025/Q3 | 2025-10-22 | -- | ±3.92% | +3.95% (beat) |
| 2025/Q2 | 2025-07-23 | -- | ±5.03% | +4.46% (in line) |
| 2025/Q1 | 2025-04-23 | -- | ±6.17% | +4.07% (in line) |
| 2024/Q4 | 2025-02-05 | -- | ±4.53% | +1.38% (in line) |
| 2024/Q3 | 2024-10-23 | -- | ±6.37% | -0.64% (in line) |
| 2024/Q2 | 2024-07-24 | -- | -- | -1.06% |
| 2024/Q1 | 2024-04-24 | -- | ±5.79% | +5.68% (in line) |
| 2023/Q3 | 2023-10-26 | -- | ±4.07% | -0.42% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:02:36 · For reference only, not investment advice and not tailored to your situation.
Boston Scientific discussion 0 comments